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Abstract: Diabetes mellitus is a chronic disease characterized by elevated blood sugar levels. In diabetic patients, oxidative stress induced
by the presence of excessive free radicals is closely associated with chronic inﬂammation, leading to potential tissue damage. Melatonin
(MEL) is a compound synthesized by the pineal gland and a scavenger of free radicals. The aim of this study was to research the effects
of MEL on oxidative stress and its DNA protective effects in streptozotocin-induced diabetic rats. In total, 32 rats were equally divided
into four experimental groups: control, melatonin, diabetic, and diabetic + melatonin. A single dose of streptozotocin (60 mg/kg) was
given by intraperitoneal route to induce experimental diabetes. MEL (10 mg/kg daily) was administrated to rats by intraperitoneal route
for 6 weeks. Oxidative stress parameters were evaluated in rat liver, kidney, brain, and pancreas tissues. Body weight, plasma glucose,
and HbA1c levels were studied. DNA damage was analyzed by comet assay in lymphocytes, while % tail DNA and mean tail moment
parameters were evaluated. The study results indicate that the intraperitoneal administration of 10 mg/kg MEL over 6 weeks may cause
amelioration in oxidative stress parameters against diabetes, leading to beneficial effects based on % tail DNA and mean tail moment
parameters in rat lymphocytes.
Key words: Diabetes mellitus, comet assay, oxidative stress, melatonin, streptozotocin, DNA damage, MDA level, tail moment, % tail
DNA, DNA repair

1. Introduction
Diabetes mellitus (DM) is a chronic disease characterized
by elevated blood sugar levels resulting from either a
lack of insulin production or a resistance to insulin. The
prevalence of DM has risen to epidemic proportions
worldwide. In diabetic patients, oxidative stress induced
by the presence of excessive reactive oxygen species (ROS)
and reactive nitrogen species (RNS) is closely associated
with chronic inﬂammation, leading to potential tissue
damage. Thus, complications of DM (such as retinopathy,
nephropathy, neuropathy, ischemic heart disease, and
peripheral vasculopathy) have now become some of the
most challenging health problems (Rochette et al., 2014;
Prattichizzo et al., 2015; Tangvarasittichai, 2015). Radicals
derived from ROS and RNS are the largest class of radical
species generated in living systems. ROS are continually
produced in the cell because of aerobic metabolism and
are controlled by several antioxidant mechanisms. ROS
and RNS are products of normal cell metabolism and have
either beneﬁcial or deleterious effects, depending on the
concentration reached in the tissues (Dalle-Donne et al.,
* Correspondence: ssekkin@adu.edu.tr
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2006). Usually, the production and neutralization of ROS
are balanced with antioxidants in a living system and do not
cause any oxidative damage. The imbalance between these
oxidants and antioxidants in the living organism system,
which determine an oxidative stress state, cause damage
to cellular macromolecules, such as lipids, proteins, and
nucleic acids (Jangra et al., 2013; Tangvarasittichai, 2015).
One of the main challenges of research in recent years has
been ﬁnding ways to attenuate oxidative stress to improve
diabetes. Therefore, it seems reasonable that antioxidants
can play an important role in the improvement of diabetes.
Many researchers reported that antioxidants have been
evaluated for the management of diabetes (Rahimi et al.,
2005; Shaker et al., 2009; Marrazzo et al., 2014; Rochette
et al., 2014).
Melatonin (MEL) is a complex synthesized by the pineal
gland in the human brain. MEL is also produced in the
retina, thymus, bone marrow, respiratory epithelium, skin,
lens, and intestine as well as in other sites. MEL modulates
a diverse number of physiological processes (Leon et
al., 2004; Tan et al., 2007). MEL acts typically through
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the widely expressed G-protein-coupled membrane
receptors MT1 and MT2. MT1 and MT2 are two wellcharacterized G-protein-coupled plasma membrane MEL
receptors, which are activated by MEL and which regulate
multiple cellular and physiological functions (Munik and
Ekmekçioğlu, 2015). MEL is a major scavenger of both
ROS and RNS reactive molecules. MEL provokes this effect
at both physiological and pharmacological concentrations.
Several of its metabolites can also detoxify free radicals
and derivatives. Both physiological and pharmacological
doses of MEL have been shown to increase gene expression
and enzyme activities of glutathione peroxidase (GPx),
glutathione reductase, superoxide dismutase (SOD), and
catalase (CAT) (Leon et al., 2004; Carpentieri et al., 2012).
Streptozotocin (STZ) is an antibiotic produced by
Streptomycetes achromogenes. However, STZ is a widely
used chemical for the induction of experimental diabetes
in rodents. STZ-induced type 1 diabetes in rodents is a
well-established and well-accepted practice for the studies
of the pathogenesis of diabetes and its complications. The
cytotoxic action of STZ is mediated by free radicals and
STZ has toxic and carcinogenic effects on the pancreas,
liver, brain, and kidneys. STZ diabetic animal models have
been very useful in clarifying the mechanisms of diabetic
pathogenesis and in screening artificial chemicals, natural
products, and pharmacological agents that are potentially
capable of lowering blood glucose levels (Jangra et al.,
2013; Wu and Yan, 2015).
The status of oxidant-antioxidant imbalance may
be one of the mechanisms leading to the DNA damage
detected in the lymphocytes of diabetic patients (GarciaRamirez et al., 2008; Arif et al., 2010; Woo et al., 2010;
Kushwaha et al., 2011). MEL, whose beneficial effects on
the antioxidant status in cells of STZ-induced diabetic rats,
may protect tissues from oxidative damage and reduce risk
of diseases caused by free radicals. Therefore, to the best
of our knowledge, no information is currently available
regarding the DNA protective effects of MEL with a comet
assay against STZ-induced diabetic rats. The present study
was designed to research the effects of MEL on oxidative
stress, as well as its DNA protective effects in STZ-induced
diabetic rats.
2. Materials and methods
2.1. Animals and experimental protocol
Thirteen-week-old male Wistar albino rats were purchased
from a commercial company (Kobay DHL A.S., Ankara,
Turkey) and the rats were acclimatized for 3 weeks. Rats
were housed in individual cages in a well-ventilated room
with a 12/12 h light/dark cycle at 22 °C. Animals were fed
with standard rat chow and tap water ad libitum (Adnan
Menderes University Experimental Animal Production
Laboratory, Aydın, Turkey). Thirty-two 16-week-old rats,
weighing 430–460 g, were randomly divided into four

experimental groups: control, melatonin, diabetic, and
diabetic + melatonin. STZ was used for experimental
diabetes (Frode and Medeiros, 2008). After 12 h of
starvation, diabetes was induced by a single intraperitoneal
(i.p.) injection of STZ, freshly dissolved in sodium citrate
buffer (0.01 M at pH 4.5) at a dose of 60 mg/kg (Wu and
Yan, 2015). At 72 h after the STZ injection, blood glucose
levels of all groups were measured using reagent strips
with a glucometer (Contour TS, Bayer, Basel, Switzerland)
in samples obtained from the tail vein. Rats having 250
mg/dL or higher blood glucose levels were considered
to be diabetic (Roy et al., 2013). The blood glucose level
and the weight of the rats were measured every week until
termination of the experiment. Rats with a ≥250 mg/dL
blood glucose level were included in the diabetic and
diabetic + melatonin groups. MEL was administrated at 10
mg/kg (i.p.) dissolved in 1 mL of 1% ethanol (Sudnikovich
et al., 2007) per day to the melatonin and melatonin +
diabetic group rats, and 1% ethanol was administered (1
mL) by i.p. route to the control and diabetic group rats
for 6 weeks. Cardiac blood (1 mL) was taken at the end
of the experiment for the quantiﬁcation of glycosylated
hemoglobin (HbA1c) by the immune turbidimetric method
(c8000 Clinical Chemistry Auto Analyzer, Abbot Architect,
Abbot Laboratories, Irving, TX, USA) (Teodoro-Morrison
et al. 2015). Animals were anesthetized at the end of the
experiment with intramuscular injections of xylazine
(Alfazyne) at 5 mg/kg and ketamine (Ketalar) at 100 mg/
kg. Cardiac blood samples were taken and processed
immediately, and liver, kidney, brain, and pancreas tissue
specimens were collected and stored at –80 °C until
analysis.
The experiments were performed in accordance with
the guide for the care and the use of laboratory animals
of the Animal Ethics Committee of Adnan Menderes
University (2015/052).
2.2. Chemicals
STZ (S0130, Sigma-Aldrich, St. Louis, MO, USA) and
MEL (M5250, Sigma-Aldrich) were used in the biological
assays. The remainder of the chemicals used were also
purchased from Sigma-Aldrich.
2.3. Tissue homogenization and determination of
antioxidant/oxidant status in tissues
Dissected liver, kidney, brain, and pancreas tissues were
immediately rinsed in ice-cold phosphate-buffered saline
(PBS). Tissues were homogenized (2000 rpm for 1 min,
1/10 w/v) using a stirrer (IKA Overhead Stirrer; IKAWerke GmbH and Co. KG, Staufen, Germany) in 10%
150 mM PBS (pH 7.4) in an ice bath. The homogenate
was centrifuged (Mikro 200 R, Hettich Zentrifugen,
Tuttlingen, Germany) at 7000 × g for 10 min at 4 °C, and
the supernatants were frozen at –80 °C (NU 9668E, Nuaire,
Plymouth, MN, USA) until they were analyzed.

933

SEKKİN et al. / Turk J Biol

2.3.1. SOD activity
SOD activity was determined according to the method of
Sun et al. (1988) and the absorbance was measured at 560
nm by a spectrophotometer (UV-1601, Shimadzu, Kyoto,
Japan). SOD estimation was based on the generation of
superoxide radicals produced by xanthine on xanthine
oxidase, which reacts with 2-(4-iodophenyl)-3-(4nitrophenyl)-5-phenyltetrazolium chloride to form a red
formazan dye. SOD activity was then measured by the
degree of inhibition of this reaction and the results are
shown as U/mg tissue protein.
2.3.2. CAT activity
CAT activity was determined according to the method of
Aebi (1984) and was measured spectrophotometrically
at 240 nm. The principle of the assay was based on the
determination of the rate constant of H2O2 decomposition
by the CAT enzyme and expressed as k/mg tissue protein,
where k is the first-order rate constant.
2.3.3. Total GSH level
The amount of glutathione (GSH) in supernatants was
measured according to the method described by Tietze
(1969): 0.5 mL of the supernatant or standard with 0.25 mL
of 1 mol/L sodium phosphate buffer (pH 6.8) and 0.5 mL
of 5-5’-dithiobis (2-nitrobenzoic acid) (DNTB, 0.8 g/L in
phosphate buffer) was left to stand for 5 min. Absorbance
was spectrophotometrically determined at 412 nm. The
results were determined by comparison with an aqueous
standard solution of GSH (Sigma Chemical Co., St. Louis,
MO, USA) and expressed as mg/g tissue protein.
2.3.4. MDA level
The concentrations of malondialdehyde (MDA) were
determined according to the method of Ohkawa et
al. (1979). The tissue homogenate was used for lipid
peroxidation estimation, which was applied by measuring
the formation of thiobarbituric acid reactive substances
(TBARS). Absorbance was measured by using a
spectrophotometer at 532 nm. The concentration of MDA
was calculated by the absorbance complex (absorbance
coefficient ε = 1.56 × 105 M–1 cm–1) and expressed as nmol/
mg tissue protein.
2.3.5. Protein concentrations
Protein concentrations in supernatants were measured by
a spectrophotometer (UV-1601, Shimadzu) with biuret,
using commercially available kits (Archem Diagnostic
Ind. Ltd., İstanbul, Turkey), and the results are expressed
as mg/mL protein.
2.4. Lymphocyte isolation and DNA analysis by comet
assay
The comet assay was applied with several modifications,
as previously described by Singh et al. (1988) and Collins
et al. (1997). For this purpose, fresh blood samples were
mixed with the PBS solution for the determination of
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DNA fragmentation of blood lymphocytes. Lymphocytes
were isolated with Histopaque and suspended in a freezing
medium. Isolated lymphocytes were slowly frozen in
aliquots of 1 mL at –80 °C (NU 9668E, Nuaire).
Conventional end-frosted slides were precoated with
1% normal melting agarose, and cells were resuspended in
PBS. This suspension was mixed with prewarmed (37 °C)
low-melting-point agarose, and two drops of this mixture
were placed on a microscope slide. A cover slip was put
on the drops, and the gels were allowed to solidify at 4 °C.
Once the gels had solidified, the cover slip was removed
and the slides were dipped into freshly prepared lysis
solution jars at 4 °C for at least 1 h. The positive control
slide cells were dipped in an H2O2 solution for 5 min at 4
°C, then washed with cold PBS and introduced into a lysis
solution in a separate jar for at least 1 h at 4 °C. Following
lysis, slides were aligned in a horizontal gel electrophoresis
tank (CSL-COM20, Cleaver Scientific, Warwickshire, UK)
that was connected to a recirculating cooler (FL300, Julabo,
Seelbach, Germany) set at 4 °C and filled with freshly made
alkaline electrophoresis solution. Electrophoresis (CS300V, Cleaver Scientific) was carried out at approximately
1 V/cm for 20 min, after which the slides were washed
twice with a neutralizing buffer and then fixed with
three different concentrations of ethanol. They were then
allowed to dry in the dark at room temperature prior to
staining with 70 µL of a 4’6-diamidino-2-phenylindole
dihydrochloride (DAPI) solution (10 µg/mL).
For the visualization of DNA damage, the slides were
examined under a fluorescence microscope (DM3000,
Leica, Wetzlar, Germany). Measurements of the tail
intensity and tail moment of comets were made for 100
randomly selected cells, i.e. 50 cells from each of two gels
from each sample, using a computer-based image analysis
system (Comet Assay IV, Perceptive Instruments, Bury St.
Edmunds, UK). The mean value of the % tail DNA and
mean tail moment parameters was calculated and used to
assess the DNA damage.
2.5. Statistical analysis
The data were compared among groups using the
Kruskal–Wallis analysis of variance (ANOVA) or one-way
ANOVA. Post hoc multiple comparisons were performed
using the Mann–Whitney U test with the Bonferroni
corrected or Duncan test (IBM SPSS Version 21.0, IBM
Corp., Armonk, NY, USA). Differences were considered
statistically significant if P < 0.05. All data were expressed
as mean and standard error.
3. Results
3.1. Body weight, blood glucose, and HbA1c levels
The mean initial body weights were similar in the control
and the other groups (P > 0.05). Diabetic rat weights were
less than those of the control and melatonin group rats
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during the 6-week period (P < 0.001). MEL administration
did not change the body weight of the rats (P > 0.05) (Table
1). The blood glucose levels of the rats were similar in the
beginning of the experiment. At 72 h following the i.p.
STZ injection, blood glucose levels were increased in the
diabetic and diabetic + melatonin groups compared with
the control and melatonin groups (P < 0.001). During
the experiment, MEL did not change the blood glucose
levels (P > 0.05) (Table 2). The serum HbA1c levels of the
diabetic (6.40 ± 0.28) and diabetic + melatonin (6.20 ±
0.30) groups were higher than those of the control (3.23
± 0.04) and melatonin (3.31 ± 0.02) groups (P < 0.001).
MEL administration was not able to decrease the serum
HbA1c levels (P > 0.05). Similarly, there was no significant
difference between the serum HbA1c levels of the diabetic
and diabetic + melatonin groups (P > 0.05).
3.2. Antioxidant/oxidant status in tissues
Among the groups, the mean SOD activities of the control
group were found to be higher in brain tissue. The SOD
activities of the diabetic group were lower, except for those

of the kidney and pancreas tissues (P < 0.01), because MEL
administration ameliorated SOD activities in the diabetic +
melatonin group’s liver and brain tissues (P < 0.001) (Figure
1A). CAT activities of the liver and kidney tissues were
lower (P < 0.05 and P < 0.001, respectively), while brain
and pancreas tissue CAT activities were not significantly
different in the diabetic group. CAT activity was higher in
the kidney tissue (P < 0.001) of the melatonin group and
the MEL administration improved the CAT activities in
the kidney tissue of the diabetic + melatonin group (Figure
1B). GSH levels of all tissues were significantly lower in
the diabetic rats compared with the control and melatonin
group rats (except brain tissue), but MEL administration
enhanced the GSH levels only in the pancreas tissue of the
diabetic + melatonin group (P < 0.01) (Figure 1C). MDA
levels were significantly higher in all tissues of the diabetic
group. MEL reduced the MDA levels of diabetes in the
liver (P < 0.001), kidney (P < 0.001), and brain (P < 0.01)
tissues, except the pancreas tissue (Figure 1D).

Table 1. Effects of MEL administration on body weight in STZ - induced diabetic rats (n = 8 per group).

Groups

Weight (g)
1st week

2nd week

3rd week

4th week

5th week

6th week

Control

497.00 ± 25.21 a

502.83 ± 24.53 a

510.70 ± 22.79 a

521.35 ± 24.51 a

526.97 ± 25.36 a 532.62 ± 25.50 a

Melatonin

490.33 ± 21.26 a,b 491.02 ± 19.55 a

476.00 ± 20.33 a

484.62 ± 21.66 a

486.26 ± 20.84 a

486.36 ± 19.87 a

Diabetic

429.62 ± 11.56 c

385.65 ± 13.67 b

369.58 ± 14.45 b

344.08 ± 12.36 b

330.73 ± 12.01 b

291.20 ± 6.93 b

Diabetic + melatonin

441.10 ± 9.40 b,c

389.81 ± 8.11 b

369.31 ± 7.72 b

353.98 ± 7.39 b

336.35 ± 6.66 b

284.36 ± 8.16 b

P

*

***

***

***

***

***

a, b, c
: Different letters indicate statistically significant differences in the same column.
*: P < 0.05, ***: P < 0.001.

Table 2. Effects of MEL administration on glucose levels in STZ-induced diabetic rats (n = 8 per group).

Groups

Glucose (mg/dL)
1st week

2nd week
105.62 ± 2.21

3rd week
105.62 ± 2.76

4th week
105.87 ± 2.14

5th week
104.87 ± 3.02

6th week
b

104.37 ± 3.59 b

Control

99.50 ± 2.58

Melatonin

109.50 ± 3.20 b

108.50 ± 3.41 c

105.87 ± 5.53 b

105.12 ± 2.51 b

108.00 ± 3.11 b

106.37 ± 2.82 b

Diabetic

379.37 ± 18.22 a

365.50 ± 33.01 b

450.62 ± 33.01 a

418.12 ± 38.71 a

502.75 ± 33.61 a

559.75 ± 6.98 a

Diabetic + melatonin

396.25 ± 26.11 a

430.25 ± 20.71 a

457.50 ± 20.84 a

487.87 ± 29.69 a

511.25 ± 23.03 a

563.00 ± 6.84 a

P

***

***

***

***

***

***

b

c

b

b

a, b, c
: Different letters indicate statistically significant differences in the same column.
***: P < 0.001.
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Figure 1. Effects of melatonin administration on the SOD (A) and CAT (B) activities as well as the GSH (C) and MDA (D) levels in
liver, kidney, brain, and pancreas tissues (n = 8 per group). a, b, c, d: Different letters indicate statistically significant differences in the
columns. NS: Not significant. *: P < 0.05, **: P < 0.01, ***: P < 0.001.

3.3 DNA analysis (% tail DNA and mean tail moment
parameters)
The effects of MEL administration on % tail DNA and
mean tail moment parameters in STZ-induced diabetic
rats are presented in Table 3. The lowest parameter
values represent minimum DNA damage at the isolated
lymphocytes in the control group. The highest values of
DNA damage were found in the diabetic group (P < 0.001).
MEL administration to the diabetic + melatonin group
reduced the % tail DNA and mean tail moment parameters
compared with the diabetic group (P < 0.001).
4. Discussion
The present research reports the effects of MEL on the
oxidative damage induced by STZ in rats and its possible
role in ameliorating damaged DNA and the development of
diabetes. The most important result of the present research
was the demonstration of a decrease in the oxidative stress
parameters, leading to a decrease in DNA damage by MEL
administered to STZ-induced diabetic rats over 6 weeks.
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Diabetes has emerged as a major threat to health
worldwide. In diabetic patients, oxidative stress induced
by the presence of excessive ROS and RNS is closely
associated with chronic inflammation, leading to potential
tissue damage. Many research studies in recent years aim
to weaken oxidative stress to improve diabetes (Oršolić et
al., 2013; Marrazzo et al., 2014; Rochette et al., 2014; Xu et
al., 2014).
At the beginning, all the experimental groups had
similar body weights, but body weights had increased only
in the control group by the end of the 6 weeks. Body weight
loss is generally observed during short- and long-term
experimental diabetes due to the overcatabolism of tissue
proteins because of hyperglycemia. In the present study,
an i.p. administration of MEL at 10 mg/kg was incapable
of stopping the body weight loss in diabetic rats (P >
0.05) and this finding supports previous research studies
(Cam et al., 2003; Sudnikovich et al., 2007; Oršolić et al.,
2011; Elbe et al., 2015; Gleissner, 2015). MEL is capable of
initiating weight loss in adult rats and plays an extra role in

SEKKİN et al. / Turk J Biol
Table 3. Effects of MEL administration on % tail DNA and mean tail moment parameters in
STZ-induced diabetic rats (n = 8 per group).

Groups

Parameters
% tail DNA

Mean tail moment

Control

12.99 ± 1.43

c

2.29 ± 0.23 c

Melatonin

18.26 ± 1.13 b

5.52 ± 0.55 b

Diabetic

41.55 ± 2.03 a

17.98 ± 1.46 a

Diabetic + melatonin

17.68 ± 1.00 b,c

5.65 ± 0.56 b

P

***

***

: Different letters indicate statistically significant differences in the same column.
*** P < 0.001.

a, b, c

the regulation of body weight through the stimulation of
brown adipose tissue metabolism (Korkmaz et al., 2012).
However, weight loss in the present study of the melatonin
group rats was not significant.
Blood glucose concentrations of diabetic rats were
more than 250 mg/dL 3 days after the STZ injection,
which showed the existence of DM. Blood glucose
concentrations were not affected by MEL treatment in
this experiment. Examined blood glucose levels were not
significantly changed at the end of the treatment among
the untreated diabetic rats and the MEL-treated diabetic
rats. This finding is in agreement with previous research
studies (Andersson and Sandler, 2001; Vural et al., 2001;
Aksoy et al., 2003), although the blood glucose levels of the
present study were different from those of some published
studies (Bibak et al., 2014; Elbe et al., 2015). Gorgun et al.
(2002) reported that the administration of MEL prior to or
after STZ treatment decreases plasma glucose and HbA1c
levels. Moreover, Andersson and Sandler (2001) reported
that DM induced by STZ (140 mg/kg intravenously) in rats
was prevented by the administration of MEL (100 mg/kg
i.p.) 30 min before STZ injection. As expected, the serum
HbA1c levels of diabetic rats were higher than those of the
nondiabetic groups (P < 0.001). Likewise, there was no
significant difference between the serum HbA1c levels of
the diabetic and diabetic + melatonin groups (P > 0.05).
Some previous studies (Montilla et al., 1998; Sudnikovich
et al., 2007) reported similar HbA1c alterations in rats.
Parallel to the blood glucose levels, the results of this study
indicate that MEL administration was unable to decrease
the serum HbA1c levels in STZ-induced diabetic rats (P >
0.05).
ROS and RNS are products of cellular metabolism and
have either deleterious or beneficial effects, depending
on the concentration reached in the tissues. In DM,
permanent hyperglycemia had been shown to lead to an

excess production of ROS. A reduced antioxidant capacity
and augmented production of ROS are the main shared
mechanisms that lead to increased oxidative stress in DM;
thus, tissue damage is facilitated. The electron transport
chain in the mitochondrial, peroxisome, and cytochrome
P450 systems are the most important sources of ROS
production, such as superoxide anion (O2•-). In addition,
various enzymes can accelerate ROS production, such as
cyclooxygenases, xanthine oxidase, uncoupled nitric oxide
synthases (NOS), and nicotinamide adenine dinucleotide
phosphate oxidases. Oxidative stress has been associated
with the major complications of DM. Cellular contents,
such as lipids, proteins, carbohydrates, and nucleic acids,
are aﬀected by alterations of the oxidant and antioxidant
equilibrium (Agil et al., 2013; Rochette et al., 2014;
Tangvarasittichai, 2015). As oxidative stress is the principal
reason for diabetic complications, the management
of antioxidants appears to be one of the most rational
restorative approaches. Studies indicate that diabetic
complications might be diminished by the administration
of various antioxidants (Rahimi et al., 2005; Di Naso et al.,
2011; Marrazzo et al., 2014; Rochette et al., 2014; Xu et al.,
2014).
In the present study, oxidative stress parameters were
evaluated based on the rats’ liver, kidney, brain, and
pancreas tissues; SOD and CAT activities; and MDA
and GSH levels. MDA was accepted as a marker of lipid
oxidation. The mechanism of lipid and protein metabolism
is diminished in the tissues of diabetic rats. The enhanced
generation of ROS, lipid peroxidation, and diminished
tissue concentrations of SOD, CAT, and GSH are reported
in both clinical and experimental diabetes (Montilla et al.,
1998; Gorgun et al., 2002; Aksoy et al., 2003; Shaker et al.,
2009; Kushwaha et al., 2011). Sudnikovich et al. (2007)
suggested that MEL might affect glucose metabolism,
thus restoring the tissue redox balance and nitric oxide
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bioavailability. Our results about MEL administration
corroborate these observations. SOD reduces intracellular
levels of superoxide radicals and converts O2•- into H2O2,
which then decomposes into water via CAT and glutathione
peroxidase. The highest SOD activity was found in the
control group rat brain tissue and the lowest activity was
found in diabetic rat tissues (except kidney and pancreas
tissues), while MEL administration ameliorated the SOD
activities in diabetic rat liver and brain tissues. CAT is
located in peroxisomes and converts H2O2 to water and
oxygen. MEL significantly enhanced the CAT activities
of the melatonin group rats, as well as in the diabetic +
melatonin group in the kidney tissues. GSH function via
GSH peroxidase is also located in the mitochondria for
the detoxification of H2O2. Increased GSH level might
have been sustained to counteract fast-generating oxygen
radicals or might have protected the cells from reactive free
radicals and peroxides. In the present study, all the tissues
of GSH levels were significantly lower in the diabetic and
diabetic + melatonin groups when compared with the
control group. However, MEL administration enhanced
the GSH levels only in the pancreas tissue of the diabetic +
melatonin group rats. Oxidative damage can induce lipid
peroxidation, depending on the increase of ROS. Lipid
peroxidation, protein oxidation, and mitochondrial DNA
mutations can be consequences of the oxidative damage
to mitochondrial components (Munik and Ekmekçioğlu,
2015). MDA levels were significantly higher in all tissues
of the diabetic rats, but MEL administration reduced the
MDA levels in the liver, kidney, and brain tissues, except
for the pancreas tissues. Comparable results were also
obtained by some researchers (Vural et al. 2001; Aksoy et
al., 2003; Eşrefoğlu et al. 2014; Elbe et al., 2015).
To the author’s knowledge, the present research reports
the first DNA protective effects of MEL demonstrated by
comet assay, probably by decreasing oxidative stress in
STZ-induced diabetic rats. We studied the DNA damage
and protection in isolated rat lymphocytes with the comet
assay. The comet assay is a reliable, simple, sensitive, and
rapid method for assessing DNA damage and repair in
the cells (Dhawan et al., 2009) and it may be used for the
purposes of evaluating the antioxidant status of the cells
(Collins, 2014). Parameters of % tail DNA and mean tail
moment were used for the evaluation of DNA damage, and
these parameters were altered by MEL administration.
We found that the DNA damage was significantly
higher in the lymphocytes of diabetic group rats compared
with the other groups. In contrast, the parameters were
significantly decreased in the diabetic + melatonin group
rats when compared with the diabetic group rats. MEL
treatment prevented STZ-induced DNA damage and
increased the DNA repair capacity in the lymphocytes
of the rats. Many researchers (Andersson and Sandler,
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2001; Kushwaha et al., 2011; Oršolić et al., 2011, 2013;
Tangvarasittichai, 2015) reported that STZ-induced
diabetes caused DNA damage. A similar result was
also observed in the present study. DNA damage was
significantly increased in STZ-induced diabetic rats. DNA
damage could be explained by increased levels of ROS
production in oxidative stress among hyperglycemic rats.
ROS inhibit glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) through a mechanism involving the activation
of enzyme poly-ADP-ribose polymerase-1 (PARP-1). This
enzyme is involved in DNA repair and apoptotic pathways.
Normally, PARP resides in the nucleus in an inactive form,
waiting for DNA damage to activate it. When increased
intracellular glucose generates increased ROS in the
mitochondria, free radicals induce DNA strand breaks,
thereby activating PARP. ROS cause strand breaks in
nuclear DNA, which activates PARP-1. PARP-1 activation
results in inhibition of GAPDH by poly-ADP-ribosylation.
GAPDH plays a critical role in DNA repairs (Brownlee,
2005; Giacco and Brownlee, 2010). Interestingly, we found
that isolated lymphocyte DNA damage of melatonin
group rats was slightly higher compared with that of
control group rats. Likewise, Cemeli et al. (2009) reported
that MEL on its own (0.1–1 mM) might generate a slight
increase in DNA damage in mammalian cells in vitro.
The DNA-protecting effect of MEL against STZinduced lipid peroxidation might be due to the free
radical scavenging property of N1-acetyl-N2-formyl-5methoxykynuramine (AFMK). AFMK is one of the most
important MEL metabolites. AFMK and structurally
different metabolites of MEL are sequentially interacting
with ROS/RNS, referred to as a scavenging cascade reaction
of MEL (Manda et al., 2007; Zhang and Zhang, 2014).
Tan et al. (2007) reported that this cascade makes MEL
highly effective as a free radical scavenger and antioxidant,
e.g., a MEL molecule might be able to scavenge up to 10
ROS/RNS. In addition to the direct effects of MEL and its
metabolites with ROS, Tan et al. (2007) stated that AFMK
and N-acetyl-5-methoxykynuramine might minimize
prooxidative and proinflammatory enzymes, as well as
accomplish free radical prevention functions. However,
we have not analyzed the MEL and AFMK statuses of
the rats in the present study. Moreover, MEL is reported
for its protective effect related to interference with DNA
damage and PARP activation by increasing cleavage of
PARP protein in cancer, methotrexate-induced intestinal
damage, and STZ-induced β-cell damage (Jangra et al.,
2013). Furthermore, MEL might regulate the antioxidant
enzyme activity at cellular mRNA levels for GPx, SOD,
and CAT, both under physiological conditions and
conditions of elevated oxidative stress. MEL might also
regulate its precursor, serotonin, which is reported to be
a lipid peroxidation inhibitor (Gorgun et al., 2002; Cemeli
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et al., 2009; Munik and Ekmekçioğlu, 2015). The examined
parameters of the present research (except mRNA
expression levels) corroborate with this phenomenon.
However, the role of neutralizing O2•- radical by MEL
is unclear in vivo. Proper functioning of mitochondria
requires sufficient ATP for virtually all functions including
repair of damage caused by ROS (Zephy and Ahmad,
2015).
In conclusion, the i.p. administration of 10 mg/kg
of MEL over 6 weeks might ameliorate oxidative stress
parameters against diabetes, thus producing beneficial

effects on % tail DNA and mean tail moment parameters in
rat lymphocytes. Therefore, the results of the study showed
that MEL might play an important role in preventing
oxidative DNA damage by scavenging excessive ROS that
were generated in hyperglycemic conditions, such as DM.
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